Fig. 4.

The proportion of patients on the same or fewer topical glaucoma medications (at left) and of those who were on glaucoma medication at screening, the proportion of patients who were on fewer topical glaucoma medications (at right) at month 12 compared to screening. In both analyses, the proportion of patients in the SE-implant group and in the FE-implant group was significantly greater than the proportion of patients in the timolol group (*P < 0.0001, chi-square test comparing each implant group to timolol). FE-implant fast-eluting travoprost intracameral implant, SE-implant slow-eluting travoprost intracameral implant